Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study.
Loschi M, Porcher R, Barraco F, Terriou L, Mohty M, de Guibert S, Mahe B, Lemal R, Dumas PY, Etienne G, Jardin F, Royer B, Bordessoule D, Rohrlich PS, Fornecker LM, Salanoubat C, Maury S, Cahn JY, Vincent L, Sene T, Rigaudeau S, Nguyen S, Lepretre AC, Mary JY, Corront B, Socie G, Peffault de Latour R. Loschi M, et al. Among authors: salanoubat c. Am J Hematol. 2016 Jun;91(4):366-70. doi: 10.1002/ajh.24278. Am J Hematol. 2016. PMID: 26689746 Free article.
Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories.
de Latour RP, Mary JY, Salanoubat C, Terriou L, Etienne G, Mohty M, Roth S, de Guibert S, Maury S, Cahn JY, Socié G; French Society of Hematology; French Association of Young Hematologists. de Latour RP, et al. Among authors: salanoubat c. Blood. 2008 Oct 15;112(8):3099-106. doi: 10.1182/blood-2008-01-133918. Epub 2008 Jun 5. Blood. 2008. PMID: 18535202 Free article.
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon FX, Guilhot F; SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC). Preudhomme C, et al. N Engl J Med. 2010 Dec 23;363(26):2511-21. doi: 10.1056/NEJMoa1004095. N Engl J Med. 2010. PMID: 21175313 Free article. Clinical Trial.
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, Aljijakli A, Rousselot P, Fenaux P, Preudhomme C, Chevret S, Dombret H; Acute Leukemia French Association. Castaigne S, et al. Lancet. 2012 Apr 21;379(9825):1508-16. doi: 10.1016/S0140-6736(12)60485-1. Epub 2012 Apr 5. Lancet. 2012. PMID: 22482940 Clinical Trial.
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries.
Díez-Campelo M, Lorenzo JI, Itzykson R, Rojas SM, Berthon C, Luño E, Beyne-Rauzy O, Perez-Oteyza J, Vey N, Bargay J, Park S, Cedena T, Bordessoule D, Muñoz JA, Gyan E, Such E, Visanica S, López-Cadenas F, de Botton S, Hernández-Rivas JM, Ame S, Stamatoullas A, Delaunay J, Salanoubat C, Isnard F, Guieze R, Pérez Guallar J, Badiella L, Sanz G, Cañizo C, Fenaux P. Díez-Campelo M, et al. Among authors: salanoubat c. Br J Haematol. 2018 May;181(3):350-359. doi: 10.1111/bjh.15190. Epub 2018 Apr 2. Br J Haematol. 2018. PMID: 29611196 Free article. Clinical Trial.
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
Garnache-Ottou F, Vidal C, Biichlé S, Renosi F, Poret E, Pagadoy M, Desmarets M, Roggy A, Seilles E, Soret L, Schillinger F, Puyraimond S, Petrella T, Preudhomme C, Roumier C, MacIntyre EA, Harrivel V, Desbrosses Y, Gruson B, Geneviève F, Thepot S, Drebit Y, Leguay T, Gros FX, Lechevalier N, Saussoy P, Salaun V, Cornet E, Benseddik Z, Veyrat-Masson R, Wagner-Ballon O, Salanoubat C, Maynadié M, Guy J, Caillot D, Jacob MC, Cahn JY, Gressin R, Rose J, Quesnel B, Guerin E, Trimoreau F, Feuillard J, Gourin MP, Plesa A, Baseggio L, Arnoux I, Vey N, Blaise D, Lacroix R, Arnoulet C, Benet B, Dorvaux V, Bret C, Drenou B, Debliquis A, Latger-Cannard V, Bonmati C, Bene MC, Peterlin P, Ticchioni M, Rohrlich PS, Arnaud A, Wickenhauser S, Bardet V, Brechignac S, Papoular B, Raggueneau V, Vargaftig J, Letestu R, Lusina D, Braun T, Foissaud V, Tamburini J, Bennani H, Freynet N, Cordonnier C, Le Garff-Tavernier M, Jacques N, Maloum K, Roos-Weil D, Bouscary D, Asnafi V, Lhermitte L, Suarez F, Lengline E, Féger F, Battipaglia G, Mohty M, Bouyer S, Ghoual O, Dindinaud E, Basle C, Puyade M, Lafon C, Fest T, Roussel M, Cahu X, Bera E, Daliphard S, Jardin F, Campos L, Solly F, Guyotat D, Galoisy … See abstract for full author list ➔ Garnache-Ottou F, et al. Among authors: salanoubat c. Blood Adv. 2019 Dec 23;3(24):4238-4251. doi: 10.1182/bloodadvances.2019000647. Blood Adv. 2019. PMID: 31869411 Free PMC article.
ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial.
Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M, Gabarre J, Casasnovas O, Jaubert J, Colin P, Delmer A, Devidas A, Bachy E, Nicolas-Virelizier E, Aoudjhane A, Humbrecht C, Andre M, Carde P; Lymphoma Study Association (LYSA). Mounier N, et al. Ann Oncol. 2014 Aug;25(8):1622-8. doi: 10.1093/annonc/mdu189. Epub 2014 May 14. Ann Oncol. 2014. PMID: 24827123 Free article. Clinical Trial.
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.
Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, Beyne-Rauzy O, Banos A, Guerci-Bresler A, Wickenhauser S, Caillot D, Laribi K, De Renzis B, Bordessoule D, Gardin C, Slama B, Sanhes L, Gruson B, Cony-Makhoul P, Chouffi B, Salanoubat C, Benramdane R, Legros L, Wattel E, Tertian G, Bouabdallah K, Guilhot F, Taksin AL, Cheze S, Maloum K, Nimuboma S, Soussain C, Isnard F, Gyan E, Petit R, Lejeune J, Sardnal V, Renneville A, Preudhomme C, Fontenay M, Fenaux P, Dreyfus F. Toma A, et al. Among authors: salanoubat c. Leukemia. 2016 Apr;30(4):897-905. doi: 10.1038/leu.2015.296. Epub 2015 Oct 26. Leukemia. 2016. PMID: 26500139 Free article. Clinical Trial.
Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia.
Fodil S, Raffoux E, Dumas PY, Desbrosses Y, Larosa F, Chantepie S, Larcher MV, Mear JB, Peterlin P, Hunault-Berger M, Hospital MA, Morel V, Lucas N, Vidal V, Salanoubat C, Michel J, Mediavilla C, Ojeda-Uribe M, Alexis M, Frayfer J, Carré M, Maillard N, Redjoul R, Banos A, Detrait M, Cluzeau T, Wickenhauser S, Chaoui D, Elassy M, Pigneux A, Dombret H, Récher C, Bertoli S; French AML Intergroup ALFA/FILO. Fodil S, et al. Among authors: salanoubat c. Leuk Lymphoma. 2021 Jul;62(7):1756-1760. doi: 10.1080/10428194.2021.1881505. Epub 2021 Feb 17. Leuk Lymphoma. 2021. PMID: 33596765 No abstract available.
35 results